Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kisspeptin's secret role in metabolism revealed?

NCT ID NCT04958109

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the hormone kisspeptin affects the body's response to sugar. Sixteen healthy adults received either kisspeptin or a placebo during an oral glucose tolerance test. Researchers measured changes in insulin sensitivity to better understand kisspeptin's role in metabolism.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
kisspeptin
What this could lead to
If successful, this could help explain how kisspeptin influences metabolism and insulin release, potentially pointing toward new treatments for metabolic diseases.
What could go wrong
This is a very small, early-phase study in healthy volunteers, so results may not apply to people with metabolic conditions. The effects of kisspeptin on glucose metabolism are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

16 people

The number who actually took part.

Started

Oct 2021

Finished

Oct 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: History: * over the age of 18, * normal pubertal development * stable weight for previous three months, * normal body mass index (BMI between 18.5-25) * regular menstrual cycles Physical examination: • systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg Laboratory studies: (per Massachusetts General Hospital reference ranges) * normal hemoglobin * hemoglobin A1C \< 6.5% * blood urea nitrogen, creatinine not elevated * aspartate aminotransferase, alanine aminotransferase \< 3x upper limit of normal Exclusion Criteria: * active illicit drug use, * history of a medication reaction requiring emergency medical care, * difficulty with blood draws. * history of chronic disease, except well controlled thyroid disease, * recent use of prescription medications which interfere with metabolism or reproduction (recent = within 5 half-lives of the drug). Use of levothyroxine or seasonal allergy medications is acceptable, * history of diabetes in a first degree relative, * use of contraceptive pills, patches or vaginal rings within last 4 weeks. * hyperlipidemia by fasting lipid panel * positive serum pregnancy test (for all women)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic diseases

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.